WHO Sounds Concern Over Critical Scarcity of Obesity Jabs
Under 10% of individuals eligible to benefit from weight-loss injections such as Wegovy have access to them, warns the WHO as it releases its inaugural advice on the medications.
Given in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable access to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The latest guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are significant obstacles to universal access to the treatments that can help people shift significant weight, explains the body.
Weight-Loss Drug Supply Crisis
Even under the present best projected scenario, the production of these medications could only cover around 100 million people – under 10% of those who need them, as stated by the health organization.
The advice urges nations and manufacturers to widen availability, by measures like voluntary licensing.
Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in a number of countries in 2026.
How Obesity Injections Work
The injections mimick a natural hormone to slow digestion, reduce hunger and increase satiety so users eat less.
Individuals commonly start to lose weight within a few weeks of starting on the weekly injections.
Studies indicates patients may put most of the weight back on within a year of stopping the treatment, when their normal appetite come back.
Being overweight or obese increases your likelihood for experiencing diseases, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight affects people in all nations and was associated with 3.7 million fatalities worldwide in 2024, according to the health agency.
